AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02379728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrenaBelt
Description: The PrenaBelt (PB) is a belt-like, positional therapy (PT) device designed for pregnant women. While the PB does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time a user spends supine via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PB is worn at the level of the waist or thorax. By design, the PB affects subtle pressure points on the user's back while supine, activating her body's natural mechanism to reposition itself to relieve discomfort, thereby reducing the amount of time spent supine.
Study NCT02379728 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Body Position Sensor
Description: The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
Study NCT04835701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Music may be played through a portable speaker in close proximity to the patient or through the patient's own headphones, if preferred. Music will be played at a low enough volume for subjects to hear standard anticipatory guidance during the procedure.
Study NCT03963687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nursing Education Intervention
Description: Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
Study NCT03963687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Nursing Education Intervention
Description: Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
Study NCT02569957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT02569957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT02569957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Given IV and PO
Study NCT04376853 — intervention group
Intervention type: DEVICE
Intervention: Apple Watch Series 5
Description: Digital monitoring via Apple Watch
Study NCT01917019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study NCT01917019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (fampridine)
Description: fampridine prolonged-release tablets
Study NCT04395430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive standard care which consist of the following:~* a lifestyle counseling visit~* educational materials~* goal-setting by a healthcare professional, and~* information about general weight management resources.~* weighing scale and measuring tape with instructions to use~* fitness tracker
Study NCT04395430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive standard care which consist of the following:~* a lifestyle counseling visit~* educational materials~* goal-setting by a healthcare professional, and~* information about general weight management resources.~* weighing scale and measuring tape with instructions to use~* fitness tracker
Study NCT04395430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online KKH Sports Singapore Program with Usual Care
Description: Participants will receive standard care and basic sports equipment and cooking materials for the online programme.~The online programme will be available up to 4 days per week (Weekdays evenings and Weekends mornings or early afternoons) and all household family members are invited to participate. The majority of the programming will be run by trained research coordinator and volunteers from KKH and Sports Singapore coaches. A regular rotation of comprehensive programming is provided, which includes online fitness, cooking, nutrition, and peer support classes. Every session includes up to 60 minutes of exercise and/or active play, and each session has an additional special 'theme.' For example, one to two sessions per week includes nutrition related programming (e.g., cooking classes), parent specific activities (e.g., a yoga class), peer support sessions (e.g., small group discussions around issues such as weight stigmatization), and fitness classes (e.g., soccer classes).
Study NCT03401541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol
Description: One capsule of 900 micrograms of 25(OH)D
Study NCT03401541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calciferol
Description: One capsule of 900 micrograms of Vitamin D
Study NCT01847118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevacizumab
Study NCT03595605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulation
Description: This group will be encouraged twice daily to ambulate
Study NCT03595605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Care as usual at inpatient NYU Langone
Study NCT04175002 — intervention group
Intervention type: DRUG
Intervention: utrogestan
Description: oral uterogeston 200mg daily to achieve window of implantation from previous study
Study NCT03840226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets
Study NCT03840226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Magnesium tablets
Study NCT01708213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aline HA
Description: Implantable dermal filler
Study NCT00908232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
Study NCT00908232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
Study NCT00908232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
Study NCT00908232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg orally daily, days 1-14 for cycles 5 to 8
Study NCT03270566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Domestic ion-exchange water softener
Description: Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
Study NCT01366287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: 25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
Study NCT01366287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: 25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
Study NCT01366287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: 25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
Study NCT01790126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARN-509
Study NCT01790126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Study NCT02354313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation.
Study NCT00455325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: First Intervention (3 weeks)
Description: once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study NCT00455325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Second Intervention (3 weeks)
Description: Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study NCT02379728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Position Sensor
Description: The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
Study NCT02379728 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-PrenaBelt
Description: The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
Study NCT00455325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Third Intervention (3 weeks)
Description: Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study NCT00455325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Fourth Intervention (3 weeks)
Description: Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study NCT02435966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
Study NCT02435966 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Dry needling
Description: Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
Study NCT02435966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Standard manual therapy in the upper trapezius or the levator scapulae
Study NCT02435966 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Manual therapy
Description: Standard manual therapy in the upper trapezius or the levator scapulae
Study NCT00490009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexxar
Description: Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~* Platelet count of 150,000/mm³ = 75 cGy~* Platelet count ≥ 100,000/mm³ but \< 150,000/mm³ = 65 cGy
Study NCT00490009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
Study NCT00490009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
Study NCT00490009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Iodide (KI)
Description: Administered to prevent thyroid blockage 130 mg orally 3 times a day,
Study NCT02159196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylcysteine and salbutamol
Description: routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
Study NCT02159196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Description: nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
Study NCT02159196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
Study NCT02953366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMS Mometasone gel
Description: The patient should administer 1 spray in each nostril once daily.
Study NCT02953366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone spray nasal
Description: The patient should administer 1 spray in each nostril once daily.
Study NCT01211197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: BI 10773 / metformin tablet
Description: BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
Study NCT01211197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: BI 10773 tablet and metformin tablet
Description: BI 10773 and metformin single tablets, administered together in fasted state
Study NCT01211197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: BI 10773 / metformin tablet
Description: BI 10773 / metformin fixed dose combination tablet in fasted state
Study NCT02702973 — intervention group
Intervention type: OTHER
Intervention: Observe the fundus characteristics after therapy.
Study NCT02977208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sparse blood sampling
Description: Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
Study NCT02977208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine sampling
Description: Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
Study NCT02977208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DNA extraction
Description: Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms
Study NCT02977208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: All patients undergoing chronic treatment with gabapentin are being recruited.
Study NCT01266135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Description: QAX576 10 mg/kg intravenous infusion
Study NCT01266135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QAX576 intravenous infusion
Study NCT04314141 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty
Description: Send a questionnaire to patients to collect informations about:~* Sexual quality of life before and after the surgery~* Satisfaction after surgery~Data collection in medical file :~* Surgery outcomes~* Functional outcomes
Study NCT03539783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory epithelial cell brushing
Description: At specified time points, nasal brushings will be performed to obtain RNA.
Study NCT03776019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVWF device
Description: The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
Study NCT03776019 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AVWF device
Description: The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
Study NCT02326012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Individual Therapy for Adolescents
Study NCT04322942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Monocyte Distribution Width
Description: Monocyte Distribution Width as part of the CBC result.
Study NCT01103635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD40 agonist monoclonal antibody CP-870,893
Description: Given IV
Study NCT01103635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Given IV
Study NCT01103635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02349451 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Study NCT02349451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-122
Study NCT02349451 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ABT-122
Study NCT02301650 — intervention group
Intervention type: DRUG
Intervention: Lamivudine
Description: mothers use Lamivudine in late pregnancy
Study NCT02301650 — intervention group
Intervention type: DRUG
Intervention: Telbivudine
Description: mothers use Telbivudine in late pregnancy
Study NCT02301650 — intervention group
Intervention type: DRUG
Intervention: Tenofovir
Description: mothers use Tenofovir in late pregnancy
Study NCT03782246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT
Description: Mindfulness- based Cognitive Therapy
Study NCT02673203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring System (CGMS)
Description: The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
Study NCT02673203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food log
Description: The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
Study NCT01268722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon angioplasty
Description: This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
Study NCT01268722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary stenting
Description: This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
Study NCT02290522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Biopsy of lesion for molecular characterization
Study NCT03672877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
Study NCT04065009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Experimental drug will be administered intraperitoneally
Study NCT04065009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo will be administered intraperitoneally